ChemGenex Launches Trial of Ceflatonin in TKI-Resistant CML

News
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 7
Volume 15
Issue 7

ChemGenex Launches Trial of Ceflatonin in TKI-Resistant CML

MENLO PARK, Calif—Chem-Genex Pharmaceuticals has launched a multinational phase II/III trial of Ceflatonin (homoharringtonine, HHT) in chronic myeloid leukemia patients who have the T315I bcr-abl point mutation, which makes them resistant to tyrosine kinase inhibitors (TKIs) such as imatinib (Gleevec). In April, FDA granted Ceflatonin orphan drug status for the treatment of CML.

Recent Videos
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML